(Q40272437)

English

Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease

scientific article published on August 1, 1979

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease (English)

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

atherosclerosis

1 reference

based on heuristic

inferred from title

Cardiology and cardiovascular medicine

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

author name string

B. Vessby

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A228684

4 June 2022

H. Lithell

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A228684

4 June 2022

I. B. Gustafsson

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A228684

4 June 2022

J. Borberg

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A228684

4 June 2022

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=228684

4 June 2022

publication date

1 August 1979

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

full work available at URL

https://api.elsevier.com/content/article/PII:0021915079900388?httpAccept=text/xml

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

https://api.elsevier.com/content/article/PII:0021915079900388?httpAccept=text/plain

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Atherosclerosis

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

457-477

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Hypercholesteremia with predisposition to atherosclerosis, an inborn error of lipid metabolism

1

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study

2

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study.

3

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Controlled trial of a diet high in unsaturated fat for prevention of atherosclerotic complications.

5

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes. A twelve-year clinical trial in men and women.

6

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Clofibrate in coronary heart disease. Effect on morbidity and mortality

7

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials

8

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

10

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Fat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders

11

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

12

0 references

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

13

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

14

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

A Methodological Study of an Intravenous Fat Tolerance Test with IntralipidREmulsion

18

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM

19

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

[On a rapid determination of the cholesterol bound to the serum alpha- and beta-lipoproteins]

20

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Quantitative and qualitative serum lipoprotein analysis. Part 1. Studies in healthy men and women

23

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

A general method for analysis of covariance structures

24

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Clinical and metabolic effects of pentaerythritol tetranicotinate in combination with cholesolvin or clofibrate.

25

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Dose-response effect of single and combined clofibrate (Atromidin®) and niceritrol (perycit®) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemia

26

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

27

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

29

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

30

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

31

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Serial lipid and lipoprotein responses to the American Heart Association fat-controlled diet

33

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

The Effect of Nicotinic Acid on the Plasma Free Fatty Acids Demonstration of a Metabolic Type of Sympathicolysis

35

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Drug treatment of hyperlipidemia

36

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

The effect of treatment with clofibrate on hepatic triglyceride and lipoprotein lipase activities of post heparin plasma in male patients with hyperlipoproteinemia

37

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia

38

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Comparison of assay methods for selective measurement of plasma lipase. The effect of clofibrate on hepatic and lipoprotein lipase in normals and patients with hypertriglyceridemia

39

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Increase of the lipoprotein-lipase activity in human skeletal muscle during clof ibrate administration

40

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Effects of clofibrate on fibrinolysis, platelet stickiness, plasma-fibrinogen, and serum-cholesterol

42

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Raised Erythrocyte Sedimentation Rate in Asymptomatic Hyperlipidaemia

43

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia.

45

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Regression and Progression of Early Femoral Atherosclerosis in Treated Hyperlipoproteinemic Patients

48

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid

49

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Effects of dietary treatment on lipoprotein levels in hyperlipoproteinaemia

16

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

18 January 2023

Identifiers

10.1016/0021-9150(79)90038-8

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40272437&oldid=1814003878"